U.S. Personal Products Stock News

Clearwater Analytics Holdings (CWAN) closed out FY 2025 with Q4 revenue of US$217.5 million and a basic EPS loss of US$0.04, as net income excluding extra items came in at a loss of US$12.1 million. Over recent periods the company has seen quarterly revenue move from US$126.5 million in Q4 FY 2024 to US$217.5 million in Q4 FY 2025, while basic EPS shifted from US$1.85 a share in Q4 FY 2024 to a loss of US$0.04 a share in the latest quarter. This sets up a results season in which investors are...

If you are wondering whether Ferguson Enterprises at around US$246.53 is still worth your attention, it helps to start by separating price moves from underlying value. The stock has seen a 7.9% decline over the last 7 days, set against returns of 4.5% over 30 days, 9.6% year to date, 46.3% over 1 year, 78.6% over 3 years and 109.5% over 5 years. This naturally raises questions about how much future strength or risk is already reflected in the price. Recent coverage of Ferguson Enterprises...

MNTN, Inc. recently reported first-quarter 2026 results, with sales rising to US$73.67 million and net income improving to US$8.76 million, reversing a net loss a year earlier and lifting basic earnings per share from continuing operations to US$0.12. On the same day, the company launched QuickFrame AI 3.0, expanding its AI-powered creative platform into a full production workflow that lets brands rapidly generate, edit, and publish multi-format video ads across major digital and TV...

Insmed (INSM) opened Q1 2026 with revenue of US$306 million and a basic EPS loss of US$0.76, while the trailing twelve months show revenue of US$820 million and a basic EPS loss of US$5.70. Over the past reported quarters, revenue has moved from US$93 million in Q1 2025 to US$306 million in Q1 2026, alongside quarterly basic EPS losses ranging between US$0.76 and US$1.75. This keeps the focus squarely on how efficiently new sales translate into narrowing losses. For investors, the story this...

Affirm Holdings (AFRM) opened its Q2 2026 update with total revenue of US$1.1b and basic EPS of US$0.39, alongside trailing twelve month revenue of US$3.7b and EPS of US$0.86 that put profitability firmly in focus. The company has seen quarterly revenue move from US$866.4m in Q2 2025 to US$1.1b in Q2 2026, while basic EPS shifted from US$0.25 to US$0.39 over the same period. This sets up this print as a key checkpoint on whether margins are starting to scale more consistently. See our full...

Wondering whether Intuitive Machines stock still offers value after its recent volatility, or if you might be turning up late to the story? The stock closed at US$24.11, with a 4.9% decline over the last 7 days, a 6.1% gain over 30 days, a 34.8% return year to date, and a 157.9% return over the past year. Recent headlines around Intuitive Machines have kept the stock in focus, with investors paying closer attention to how its projects translate into long term potential. This context helps...

eXp World Holdings (AGNT) recently drew attention after eXp Commercial added veteran broker Mario J Alvarez Jr, whose two decades in commercial real estate align with the company’s effort to grow its investment sales presence. See our latest analysis for eXp World Holdings. At a share price of $6.60, eXp World Holdings has a 30 day share price return of 10.18% and a 7 day gain of 2.48%. However, the year to date share price return of 27.47% and 90 day share price return of 23.79% point to...

Wondering whether Taiwan Semiconductor Manufacturing stock still offers value after its strong run, or if you might be arriving late to the story? The share price last closed at US$414.15, with returns of 4.6% over 7 days, 19.9% over 30 days, 29.6% year to date, 138.6% over 1 year, 413.9% over 3 years and 306.3% over 5 years. Recent headlines have focused on Taiwan Semiconductor Manufacturing's central role in global chip supply and its position in advanced manufacturing capacity. This...

If you are wondering whether Grindr stock is priced fairly or if the current level still leaves room for value, you need to look past headlines and into the numbers that shape valuation. Over the last month the share price has moved to US$13.81, with returns of 3.3% over 7 days, 12.4% over 30 days and 3.8% year to date, set against a 43.5% loss over the past year and a 124.2% gain over three years. Recent coverage has focused on Grindr as a listed platform business and how investors are...

If you are trying to figure out whether Apellis Pharmaceuticals is attractively priced today, it helps to start with how the current market value lines up against different ways of estimating fair value. The stock last closed at US$41.01, with returns of 0.1% over 7 days, 0.8% over 30 days, 58.6% year to date and 130.3% over the past year, alongside 3 year and 5 year returns of 53.7% decline and 10.1% decline respectively. This gives a mixed picture for anyone thinking about entry or exit...

Vistra (VST) has wrapped up FY 2025 with fourth quarter revenue of US$4.6b, Basic EPS of US$0.55 and net income of US$185m, rounding out a trailing twelve month picture that totals US$17.7b in revenue, Basic EPS of US$2.22 and net income of US$752m. Over recent quarters, reported revenue has moved from US$4.0b in Q4 2024 to US$4.6b in Q4 2025, while quarterly Basic EPS has ranged from US$1.16 in Q4 2024 to US$0.55 most recently, setting up a results season where investors are weighing...

Earlier this week, enGene Therapeutics reported interim Phase 2 LEGEND trial results for its bladder cancer gene therapy detalimogene voraplasmid, revealing a 54% complete response rate but weaker 12‑month durability than previously expected, alongside generally manageable side effects and low disease progression. The mixed efficacy profile has triggered analyst downgrades and shareholder-rights investigations, highlighting how a single data update can rapidly reshape perceptions of a...

If you are wondering whether Planet Labs PBC at around US$35.24 is priced attractively or already baking in big expectations, it helps to step back and look at how the stock has been behaving and what that might imply about value. The share price is around US$35.24, with a 4.7% decline over the last week, roughly flat at 0.2% over the past month, a 72.7% gain year to date, and a very large rise over the past year that is close to 9x, as well as very strong multi year returns. These moves...

NiSource (NYSE:NI) announced new and expanded partnerships with Amazon and Alphabet that are expected to support $1.4 billion in customer savings over 15 years. Alongside these partnerships, the company updated its long term adjusted EPS growth outlook to a range of 9% to 10% through 2033. For investors watching utilities, NiSource stands out with a current share price of $47.02 and a 5 year return of 115.2%. The stock has also returned 21.9% over the past year and 83.7% over 3 years,...

This article examines whether Primo Brands, trading at around US$22.24, currently represents value or risk by exploring what the share price might be implying. The stock has returned 9.1% over the last 7 days, 21.3% over the last 30 days and 37.4% year to date, while the 1 year return reflects a 29.8% decline and the 3 and 5 year returns are 69.8% and 48.4% respectively. Recent market interest in Primo Brands appears tied to broader investor attention on beverage companies listed in the US...

Guardant Health (GH) has just posted its FY 2025 numbers with Q4 revenue of US$281.3 million, a basic EPS loss of US$1.00 and net income loss of US$128.5 million, set against a trailing twelve month revenue base of US$982.0 million and a TTM EPS loss of US$3.32. Over recent quarters the company has seen revenue move from US$201.8 million in Q4 FY 2024 to US$281.3 million in Q4 FY 2025. Quarterly basic EPS losses have ranged between US$0.74 and US$1.00, and TTM net income losses have remained...

Encore Capital Group (NasdaqGS:ECPG) is asking shareholders to approve an amendment to its corporate charter. The change would exculpate company officers from personal liability for monetary damages tied to breaches of the duty of care. The proposal is scheduled for a vote at the upcoming annual shareholder meeting. Encore Capital Group operates in the consumer debt buying and collections space, where regulatory scrutiny, legal risk and reputational considerations tend to be front and...

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations. The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk. Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline...

Wondering whether Privia Health Group at around US$23.99 is offering fair value or a potential opportunity? This article breaks down what the current price may be telling you. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 7.2% gain over the last 30 days, and year to date returns of 2.3% after a 4.3% loss over the past year. Those mixed returns come against a backdrop of ongoing interest in healthcare services companies focused on physician enablement and...

Motorola Solutions (MSI) closed out FY 2025 with fourth quarter revenue of US$3.4 billion and basic EPS of US$3.90, supported by net income of US$649 million. Trailing 12 month figures show revenue of US$11.7 billion and basic EPS of US$12.93. Over the past year, revenue has moved from US$10.8 billion to US$11.7 billion and basic EPS has gone from US$9.45 to US$12.93, alongside trailing 12 month net income rising from US$1.6 billion to US$2.2 billion. This sets the backdrop for a profit story...

If you are wondering whether IonQ's current share price lines up with its fundamentals, this article walks through the key signals investors often rely on when thinking about value. The stock last closed at US$47.68, with returns of 5.7% over 7 days, 67.4% over 30 days, 1.9% year to date and 49.7% over 1 year. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage has focused on IonQ as a pure play in quantum computing, with attention on...

Wondering whether Verra Mobility stock is starting to look appealing at its current price, especially after a tough run? This article focuses squarely on what that price might really imply about value. The stock last closed at US$14.63 and has returned 0.5% over 30 days, yet year to date it is down 34.5% and the 1 year return is a 39.7% decline, which can change how investors think about both risk and opportunity. Recent coverage has focused on how the stock's weaker 1 year and 3 year...

Serve Robotics (SERV) has posted FY 2025 results that highlight a small but growing top line alongside sizable losses, with Q4 revenue at about US$0.9 million and a quarterly net loss of roughly US$34.3 million, or EPS of US$0.46 loss, while trailing 12 month revenue sits at roughly US$2.7 million against a net loss of about US$101.4 million and EPS of US$1.63 loss. Over recent quarters the company has seen revenue move from around US$0.18 million in Q4 FY 2024 to US$0.88 million in Q4 FY...

Akebia Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$53.54 million versus US$57.34 million a year earlier, with net loss of US$9.05 million replacing prior net income of US$6.11 million. A recent proposal to increase authorized capital stock to 525,000,000 shares, including 500,000,000 common shares, adds a potential dilution and financing angle to Akebia’s weaker quarterly performance. Next, we’ll examine how the shift to a quarterly loss alongside...